I'm curious how the benefit-risk assessment for this approval works since both the benefits and risks of the vaccine appear to be negligible in this age group.

I'm curious how the benefit-risk assessment for this approval works since both the benefits and risks of the vaccine appear to be negligible in this age group. Sure it produces antibodies. It's good that it's "sort of effective" for a few months after the second dose (numbers like 50% and 30% effective over a very short follow-up period ie not very). We're told it reduces risk of severe disease and that's plausible but I don't see any indication that was actually measured for this age group (or at least, they didn't mention those results in the announcement). So, why?